Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809783 | 1.00 | LMNA (0.44) | LMNAACHEGAAKMT2ATDP1 | |
| SCHEMBL2813061 | 0.85 | LMNA (0.46) | LMNAACHEGAAKMT2ATDP1 | |
| SCHEMBL2813058 | 0.85 | LMNA (0.46) | LMNAACHEGAAKMT2ATDP1 | |
| SCHEMBL2813105 | 0.83 | RECQL (0.40) | KMT2ATDP1L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL2813106 | 0.83 | RECQL (0.40) | KMT2ATDP1L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL2811889 | 0.82 | MAPT (0.41) | LMNAGAAKMT2ATDP1L3MBTL1 | |
| SCHEMBL2811892 | 0.82 | MAPT (0.41) | LMNAGAAKMT2ATDP1L3MBTL1 | |
| SCHEMBL2808634 | 0.80 | HTT (0.50) | LMNAKMT2AL3MBTL1POLBSMN1; SMN2 | |
| SCHEMBL2811132 | 0.80 | POLB (0.46) | LMNAGAAKMT2AL3MBTL1POLB | |
| SCHEMBL2808632 | 0.80 | HTT (0.50) | LMNAKMT2AL3MBTL1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278473-B2 | Alpha, beta-unsaturated imidate compound and pesticidal composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| US-20100240729-A1 | ALPHA, BETA-UNSATURATED IMIDATE COMPOUND AND PESTICIDAL COMPOSITION CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-23 | — | — | US | disclosed |
| WO-2009064031-A1 | ALPHA, BETA-UNSATURATED IMIDATE COMPOUND AND PESTICIDAL COMPOSITION CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240729-A1 | ALPHA, BETA-UNSATURATED IMIDATE COMPOUND AND PESTICIDAL COMPOSITION CONTAINING THE SAME | OXER1, CBR1, DEGS1 | LMNA 2201/4885ACHE 49/4885GAA 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.